Literature DB >> 14988595

Mesangiocapillary glomerulonephritis type 2 associated with familial partial lipodystrophy (Dunnigan-Kobberling syndrome).

Katharine R Owen1, Mollie Donohoe, Sian Ellard, Tom J Clarke, Anthony J Nicholls, Andrew T Hattersley, Coralie Bingham.   

Abstract

The lipodystrophies are a heterogeneous group of disorders of adipose tissue associated with insulin resistance. The sporadic form of partial lipodystrophy, characterised by fat loss from the face and upper body, is associated with complement abnormalities and mesangiocapillary glomerulonephritis type 2 (MCGN II) and the conditions are thought to have a shared autoimmune aetiology. We present the first case of the rare familial form of partial lipodystrophy, caused by a mutation in the LMNA gene, associated with MCGN II. This suggests that partial lipodystrophy of both the sporadic and familial subtypes may predispose to this condition and that the observed renal and complement abnormalities may be secondary to other factors associated with lipodystrophy. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14988595     DOI: 10.1159/000076396

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  8 in total

1.  American Society of Nephrology clinical pathological conference.

Authors:  Kevin E Meyers; Helen Liapis; Mohamed G Atta
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

2.  Renal complications of lipodystrophy: A closer look at the natural history of kidney disease.

Authors:  Baris Akinci; Sadiye Mehtat Unlu; Ali Celik; Ilgin Yildirim Simsir; Sait Sen; Banu Nur; Fatma Ela Keskin; Basak Ozgen Saydam; Nilufer Kutbay Ozdemir; Banu Sarer Yurekli; Bekir Ugur Ergur; Melda Sonmez; Tahir Atik; Atakan Arslan; Tevfik Demir; Canan Altay; Ulku Aybuke Tunc; Tugba Arkan; Ramazan Gen; Erdal Eren; Gulcin Akinci; Aslihan Arasli Yilmaz; Habib Bilen; Samim Ozen; Aygul Celtik; Senay Savas Erdeve; Semra Cetinkaya; Huseyin Onay; Sulen Sarioglu; Elif Arioglu Oral
Journal:  Clin Endocrinol (Oxf)       Date:  2018-05-17       Impact factor: 3.478

3.  A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease.

Authors:  Hitomi Imachi; Koji Murao; Shouji Ohtsuka; Mako Fujiwara; Tomie Muraoka; Hitoshi Hosokawa; Toshihiko Ishida
Journal:  Endocrine       Date:  2008-11-15       Impact factor: 3.633

4.  Membranous glomerulonephritis with an LMNA mutation.

Authors:  Kumi Fujita; Kazuhiro Hatta
Journal:  CEN Case Rep       Date:  2018-01-18

5.  Long-term fundus changes in acquired partial lipodystrophy.

Authors:  Joyce Jansen; Lien Delaere; Leigh Spielberg; Anita Leys
Journal:  BMJ Case Rep       Date:  2013-11-18

6.  Quantitative PPARγ expression affects the balance between tolerance and immunity.

Authors:  Ya-Hui Liu; Yau-Sheng Tsai; Shih-Chieh Lin; Nan-Shih Liao; Ming-Shiou Jan; Chung-Tiang Liang; Shih-Wen Hsu; Wen-Chung Chen; Junne-Ming Sung; Nobuyo Maeda; Pei-Jane Tsai
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

7.  Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T LMNA mutation.

Authors:  Athanasios Fountas; Zoe Giotaki; Evangelia Dounousi; George Liapis; Alexandra Bargiota; Agathocles Tsatsoulis; Stelios Tigas
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-06-02

Review 8.  The renal manifestations of type 4 familial partial lipodystrophy: a case report and review of literature.

Authors:  Ru-Xuan Chen; Lei Zhang; Wei Ye; Yu-Bing Wen; Nuo Si; Hang Li; Ming-Xi Li; Xue-Mei Li; Ke Zheng
Journal:  BMC Nephrol       Date:  2018-05-10       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.